State Street Corp Verona Pharma PLC Transaction History

State Street Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$15.3 - $20.24 $73,256 - $96,909	-4,788 Reduced 12.48%	33,572 $540,000
Q3 2023 Nov 14, 2023	BUY	$16.3 - $22.09 $334,150 - $452,845	20,500 Added 114.78%	38,360 $625,000
Q2 2023 Aug 14, 2023	SELL	$19.41 - $23.43 $737,948 - $890,785	-38,019 Reduced 68.04%	17,860 $377,000
Q1 2023 May 15, 2023	BUY	$18.06 - $25.27 $801,972 - $1.12 Million	44,406 Added 387.05%	55,879 $1.12 Million
Q4 2022 Feb 14, 2023	SELL	$9.84 - $26.13 $4.31 Million - $11.4 Million	-437,556 Reduced 97.44%	11,473 $299,000
Q3 2022 Nov 15, 2022	BUY	$4.14 - $13.59 $1.86 Million - $6.1 Million	449,029 New	449,029 $4.23 Million

167

68.7M

704K

685K

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $2.75B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.